ESALY News and Press, Eisai Co. Ltd. ADR

2023-12-05 03:58:10 ET Summary Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anav...

2023-07-03 06:49:30 ET Summary We check in on Catalyst Pharmaceuticals today as a lot has happened around the company since we last looked at it last summer. These include a major addition to the company's pipeline, challenges on the patent litigation front, and impressive organic...

Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...

Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...

Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration TOKYO, May 8, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into a joint development agreement with Bliss Biop...

Eisai Completes a Major Renovation of Tsukuba Research Laboratories TOKYO, Apr 6, 2023 - (JCN Newswire) - Eisai Co., Ltd. today announced the completion of a major renovation of its Tsukuba Research Laboratories (Ibaraki, Japan), which is a part of strategic investment to execute Ei...

Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal TOKYO, Apr 4, 2023 - (JCN Newswire) - Eisai Co., Ltd. today announced an article about long-term health outcomes of anti-amyloid...

Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on "Patient-Proposed Healthcare Services" System TOKYO, Apr 3, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it h...

Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals TOKYO and CAMBRIDGE, Mass., Mar 31, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that three additional detailed analy...